More than 40 US states have filed a lawsuit accusing pharmaceutical firms of conspiring to artificially inflate the cost of common medicinal drugs.
Inflating the cost of drugs isn’t the exception in the pharma industry, it’s the rule. This is because the vast profits made by pharma companies are based on the patenting of their drugs. Obtaining a patent for a drug essentially allows its manufacturer to arbitrarily set the price at which it is sold. When a drug is the first to be authorized by regulators to treat a specific disease, or when it supposedly treats a disease more effectively than other drugs, the company that manufactures it effectively becomes able to control the ‘market’ for that disease.
However, while the marketplace for pharma companies is the human body, this only remains the case so long as the body hosts diseases. As such, ensuring the continued existence of diseases and increasing their incidence is a precondition for the growth of the pharma industry.
A key strategy to accomplish this goal is the development of drugs that merely mask symptoms and avoid the cure or elimination of diseases. As the prevention and root cause treatment of diseases decreases the long-term profitability of the pharma industry, the use of such an approach is avoided or even outright obstructed by it.
To learn more about the unethical ways in which the pharma industry operates, see the ‘Laws of the Pharmaceutical Industry’ feature on our website.